Diferido
Otros sitios de cotización
|
Varia. Cinco días. | Varia. 1 de enero. | ||
100,4 USD | -1,56 % | +0,87 % | +0,41 % |
10/05 | Scemblix de Novartis recibe la tercera designación de terapia innovadora de la FDA estadounidense | MT |
06/05 | NOVARTIS AG : Recibe una recomendación de compra del UBS | ZD |
Resumen de negocios
- oncología (29,9%);
- inmunología (17,2%)
- enfermedades cardiovasculares, renales y metabólicas (14,1%)
- neurociencia (8,9%).
El resto de las ventas netas (29,9%) procede de la fabricación por contrato de productos farmacéuticos.
A finales de 2023, Novartis AG contaba con 33 centros de producción en todo el mundo.
Las ventas netas se distribuyen geográficamente de la siguiente manera: Europa (33%), Estados Unidos (39,5%), Asia/África/Australasia (20,5%), Canadá y Latinoamérica (7%).
Número de empleados: 76 057
Ventas por actividad
CHF en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Established Brands
30,0
%
| - | - | 12 238 | 30,0 % | - |
Oncology
29,9
%
| - | - | 12 213 | 29,9 % | - |
Immunology
17,2
%
| - | - | 7 008 | 17,2 % | - |
Cardiovascular, Renal and Metabolic
14,1
%
| - | - | 5 743 | 14,1 % | - |
Neuroscience
8,9
%
| - | - | 3 633 | 8,9 % | - |
Ventas por región
CHF en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
39,5
%
| 16 860 | 34,9 % | 16 139 | 39,5 % | -4,28 % |
Europe
18,9
%
| 10 469 | 21,7 % | 7 704 | 18,9 % | -26,41 % |
Asia/Africa/Australasia
9,1
%
| 4 975 | 10,3 % | 3 700 | 9,1 % | -25,63 % |
Germany
7,4
%
| 4 086 | 8,5 % | 3 026 | 7,4 % | -25,94 % |
China
7,2
%
| 2 987 | 6,2 % | 2 936 | 7,2 % | -1,73 % |
Canada and Latin America
7,0
%
| 3 709 | 7,7 % | 2 854 | 7,0 % | -23,04 % |
Japan
4,2
%
| 2 106 | 4,4 % | 1 729 | 4,2 % | -17,90 % |
France
3,8
%
| 2 156 | 4,5 % | 1 572 | 3,8 % | -27,09 % |
Switzerland
2,9
%
| 926 | 1,9 % | 1 175 | 2,9 % | +26,88 % |
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
Chief Executive Officer | 48 | 01/01/05 | |
Director of Finance/CFO | 59 | 01/01/03 | |
Shreeram Aradhye
CTO | Chief Tech/Sci/R&D Officer | 62 | 16/05/22 |
Steffen Lang
COO | Chief Operating Officer | 57 | 01/04/17 |
Klaus Moosmayer
CMP | Compliance Officer | 56 | 01/12/18 |
Samir Shah
IRO | Public Communications Contact | 63 | 01/01/04 |
Simon Brown
PRN | Corporate Officer/Principal | - | 01/08/13 |
Kees Roks
AUD | Comptroller/Controller/Auditor | 61 | 01/05/22 |
Linda Kanitra
PRN | Corporate Officer/Principal | - | - |
Robert Kowalski
HRO | Human Resources Officer | 56 | 01/09/21 |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Bill Winters
BRD | Director/Board Member | 62 | 01/01/13 |
Simon Moroney
BRD | Director/Board Member | 65 | 28/02/20 |
Chairman | 68 | 01/01/13 | |
John Young
BRD | Director/Board Member | 60 | 07/03/23 |
Bridgette Heller
BRD | Director/Board Member | 62 | 28/02/20 |
Ton Büchner
BRD | Director/Board Member | 59 | 01/01/16 |
Charles Sawyers
BRD | Director/Board Member | 65 | 01/01/13 |
Nancy Andrews
BRD | Director/Board Member | 65 | 01/01/15 |
Patrice Bula
BRD | Director/Board Member | 68 | 28/02/19 |
Frans van Houten
BRD | Director/Board Member | 64 | 28/02/17 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 1 | 2 189 930 497 | 1 866 336 959 ( 85,22 %) | 233 443 766 ( 10,66 %) | 85,22 % |
Participaciones
Nombre | Acciones | % | Valoración |
---|---|---|---|
NOVARTIS AG 6.63% | 145 083 991 | 6.63% | 14 086 822 744 $ |
SANDOZ GROUP AG 4.30% | 18 524 209 | 4.30% | 629 154 567 $ |
MORPHOSYS AG 11.56% | 4 360 100 | 11.56% | 308 626 844 $ |
NOVARTIS INDIA LIMITED 70.68% | 17 450 680 | 70.68% | 216 480 572 $ |
THIRD HARMONIC BIO, INC. 6.48% | 2 642 762 | 6.48% | 27 643 291 $ |
ERASCA, INC. 8.12% | 12 307 692 | 8.12% | 23 138 461 $ |
OCULIS HOLDING AG 4.68% | 1 713 521 | 4.68% | 20 476 576 $ |
MOLECULAR PARTNERS AG 4.78% | 1 739 130 | 4.78% | 6 238 607 $ |
413 581 | 5.98% | 4 020 007 $ | |
GAMIDA CELL LTD. 2.82% | 4 336 759 | 2.82% | 78 062 $ |
Información de la empresa
Empresas del grupo
Nombre | Categoría y sector |
---|---|
Novartis Healthcare Pvt Ltd.
Novartis Healthcare Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Novartis AG, Novartis Healthcare Pvt Ltd. is an Indian company that manufactures and markets health care and nutritional products. The private company is based in Mumbai, India. The company was founded in 1997. The CEO is Sanjay Prabhakar Murdeshwar. |
Pharmaceuticals: Major
|
Novartis Services, Inc.
| |
Novartis International AG
Novartis International AG Pharmaceuticals: MajorHealth Technology Novartis International AG manages the Novartis Group. It provides administrative, financial, legal, and technical services. It also offers scientific consultation to the Group. The company was founded on December 13, 1989 and is headquartered in Basel, Switzerland. |
Pharmaceuticals: Major
|
Novartis Pharma AG
Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. |
Pharmaceuticals: Major
|
Novartis Pharma GmbH
Novartis Pharma GmbH Pharmaceuticals: MajorHealth Technology Novartis Pharma GmbH engages in the production and sale of pharmaceutical products. The firm establishes and operates institutes for the development of medicinal products. It also conducts research and development in the field of pharmacy. The company was founded by Johann Rudolf Geigy-Gemuseus in 1758 and is headquartered in Vienna, Austria. |
Pharmaceuticals: Major
|
Sandoz GmbH
Sandoz GmbH Pharmaceuticals: MajorHealth Technology Sandoz GmbH manufactures generic pharmaceuticals and biotechnological drugs. Its products includes bio-similars, inhalers, patches, injectables, and oral solids. The company was founded in 1946 and is headquartered in Kundl, Austria. |
Pharmaceuticals: Major
|
Alcon Ophthalmika GmbH
| |
EBEWE Pharma Ges.m.b.H. Nfg.KG
EBEWE Pharma Ges.m.b.H. Nfg.KG Pharmaceuticals: MajorHealth Technology EBEWE Pharma Ges.m.b.H. Nfg.KG engages in the development and manufacture of injectable pharmaceutical specialties. The firm offers therapy solutions for colon, lung, breast, and prostate cancer. It also specializes in drug and pharmaceutical development, as well as preclinical studies. The company was founded in 1934 and is headquartered in Unterach am Attersee, Austria. |
Pharmaceuticals: Major
|
Pharmaceuticals: Major
|
Ventas por actividad
Ventas por región
Revisiones del BPA
Varia. 1 de ene. | Capi. | |
---|---|---|
+31,49 % | 588 mil M | |
-3,27 % | 364 mil M | |
+19,39 % | 326 mil M | |
+5,23 % | 285 mil M | |
+15,33 % | 239 mil M | |
-7,08 % | 200 mil M | |
+9,51 % | 167 mil M | |
-0,49 % | 161 mil M | |
+1,21 % | 124 mil M |
- Bolsa de valores
- Acciones
- Acción NOVN
- Acción NVSEF
- Empresa Novartis AG